New Data on Arformoterol for Respiratory Death, COPD Hospitalization
Sunovion announced data from a one-year study on the risk of respiratory death or chronic obstructive pulmonary disease (COPD) exacerbation-related hospitalization in patients taking arformoterol tartrate (Brovana). The results were published in the CHEST Journal.
In the multicenter, double-blind, randomized Large Simple Safety Study (LSSS), 841 patients aged ≥40 years with baseline FEV1 ≤65% predicted, FEV1 >0.50L, FEV1/FVC ≤70%, and ≥15 pack-year smoking history received 15mcg of arformoterol daily (n=420) or placebo (n=421) over the course of one year; 466 patients completed one year of the study.
Patients taking arformoterol experienced fewer COPD exacerbation-related hospitalizations compared to placebo (9.0% vs. 14.3%, respectively) and fewer primary events such as respiratory death or first COPD exacerbation-related hospitalization (9.5% vs. 15.0%, respectively). Risk for first respiratory serious adverse event was also 50% lower in patients taking arformoterol vs. placebo. Overall, arformoterol demonstrated a ~40% lower risk of respiratory death or COPD exacerbation-related hospitalization over 1 year vs. placebo.
Arformoterol is a long-acting beta-2 agonist indicated for the long-term maintenance treatment of bronchoconstriction due to COPD in adults.
For more information call (800) 739-0565 or visit Sunovion.com.